CORRECTION

Correction: Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer

The *PLOS ONE* Staff

The statement in the Funding section incorrectly reproduces the Competing Interests statement. The publisher apologizes for the error. The correct Funding statement is: Support for this study included departmental funds from the Department of Biostatistics and Bioinformatics, the Biostatistics and Bioinformatics Shared Resource, and Lung Cancer Center of Excellence at the H. Lee Moffitt Cancer Center & Research Institute, Stand Up To Cancer (SU2C-AACR-CT04-17), and the National Institutes of Health (5P30CA076292).

Reference

1. Chen D-T, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, et al. (2021) Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. *PLoS ONE* 16(7): e0252041. <https://doi.org/10.1371/journal.pone.0252041> PMID: 34197475

OPEN ACCESS

Citation: The *PLOS ONE* Staff (2021) Correction: Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. *PLoS ONE* 16(7): e0255429. <https://doi.org/10.1371/journal.pone.0255429>

Published: July 23, 2021

Copyright: © 2021 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.